Fundraising Fox

Asgard Therapeutics

Lund, SE · Founded 2018 · 29 employees on LinkedIn · 4 known investors

Find your way into Asgard Therapeutics

321 people in our graph share verified history with the Asgard Therapeutics team — schools, employers, funds. One of them is your warm intro.

Deji Sasegbonunlockedknows Filipe Pereira · together at Imperial College London (overlapped)
×4knows the team · via Imperial College London
×5knows the team · via Lund University
×2knows the team · via Universidade do Porto

Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Asgard Therapeutics was founded in 2018 by Cristiana Pires, Fábio Rosa, and Filipe Pereira.

CPCristiana Pires
Cristiana PiresinCo-founder and CEO
FRFábio Rosa
Fábio RosainCo-founder and VP of ResearchFábio Rosa studied transcription factors and cellular reprogramming during his research career, focusing on methods to induce dendritic cell fate. He is co-founder and VP of Research at Asgard Therapeutics, a cancer immunotherapy company developing direct cell reprogramming technologies.
FPFilipe Pereira
Filipe PereirainCo-founder and Head of InnovationFilipe Pereira is a Professor of Molecular Medicine at Lund University with 20 years of research experience in cellular reprogramming and immunology. He earned his Ph.D. from Imperial College London and conducted postdoctoral research at Mount Sinai, where he developed approaches to apply cellular reprogramming to hematopoiesis; he co-founded Asgard Therapeutics to translate dendritic cell reprogramming into cancer immunotherapy.

Investors · 4

IndustrifondenStockholm · $1.1M – $4.3M
LU InnovationLund
Novo HoldingsCopenhagen · $1.1M – $54M
Boehringer Ingelheim Venture Fundreported · 2 sourcesIngelheim am Rhein · $16.2M

Funding

SEC filings, press & company announcements

$30M disclosed across 1 of 2 rounds · 2021–2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 - BioSpacebiospace.com · Apr 2026Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncologyprnewswire.com · Mar 2024Asgard Therapeutics Raises €30M in Series A Financingfinsmes.com · Mar 2024Team – ASGARD THERAPEUTICSasgardthx.com · Mar 2022Asgard Therapeutics raises EUR 6M in Seed Financing to exploit direct in vivo reprogramming - Asgard Therapeuticsasgardthx.com · Nov 2021Asgard Therapeutics – SmiLe Venture Hubsmileventurehub.com · Nov 2020

Frequently asked questions

What does Asgard Therapeutics do?
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.
Who founded Asgard Therapeutics?
Asgard Therapeutics was founded by Cristiana Pires, Fábio Rosa, Filipe Pereira in 2018.
Who are Asgard Therapeutics's investors?
Asgard Therapeutics's investors include Industrifonden, LU Innovation, Novo Holdings, Boehringer Ingelheim Venture Fund.
How much funding has Asgard Therapeutics raised?
Asgard Therapeutics has disclosed $30M raised across 1 of its 2 known rounds.
Where is Asgard Therapeutics headquartered?
Asgard Therapeutics is headquartered in Lund, SE.